Alpha DaRT holds a Japan approval and a pivotal cSCC readout due year-end — the question is whether single-arm data can clear FDA's PMA bar across multiple indications

Alpha Tau Medical is a clinical-stage company developing an intratumoral radiotherapy treatment for cutaneous squamous cell carcinoma and other cancers, with its lead product already approved in Japan but not yet approved in the United States.

Alpha Tau's intratumoral alpha-particle radiotherapy, Alpha DaRT, has already secured a Japanese marketing approval for head and neck cancer and completed enrollment of 88 patients in a U.S. pivotal trial for recurrent cutaneous squamous cell carcinoma, with year-end data determining whether the company can achieve U.S. PMA on single-arm ORR and DOR endpoints. The GBM and pancreatic programs remain early and speculative, but the 100% ORR combination data in HNSCC and pooled pancreatic OS data exceeding historical controls suggest broad platform potential. The principal risk is FDA skepticism toward single-arm device approval in oncology, a non-standard pathway where the bar for approvability without a randomized control remains uncertain.